November 28, 2011
Seventy-Four Percent of Surveyed U.S. Neurologists Indicate They Will Prescribe Biogen Idec’s BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis
- /
- /
- /
- /
Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that 74 percent…
